Evidence map›Paper›PMID 32107310›Full record

ArticleThe Journal of biological chemistry2020

The luminescent HiBiT peptide enables selective quantitation of G protein-coupled receptor ligand engagement and internalization in living cells.

Michelle E Boursier, Sergiy Levin, Kris Zimmerman, Thomas Machleidt, Robin Hurst, Braeden L Butler, Christopher T Eggers, Thomas A Kirkland, Keith V Wood, Rachel Friedman Ohana

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 69 citations in OpenAlex.

  1. CRISPR Gene Tagging for Illuminating Endogenous Protein Dynamics.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Serotonin 5-HTACS chemical neuroscience · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Luciferase complementation for cellular assays beyond protein-protein interactions.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Molecular pharmacology · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Michelle E BoursierPromega Corporation, Fitchburg, Wisconsin 53711.ORCID 0000-0002-2642-1802
Sergiy LevinPromega Biosciences LLC, San Luis Obispo, California 93401.
Kris ZimmermanPromega Corporation, Fitchburg, Wisconsin 53711.
Thomas MachleidtPromega Corporation, Fitchburg, Wisconsin 53711.
Robin HurstPromega Corporation, Fitchburg, Wisconsin 53711.
Braeden L ButlerPromega Corporation, Fitchburg, Wisconsin 53711.
Christopher T EggersPromega Corporation, Fitchburg, Wisconsin 53711.
Thomas A KirklandPromega Biosciences LLC, San Luis Obispo, California 93401.
Keith V WoodPromega Corporation, Fitchburg, Wisconsin 53711.
Rachel Friedman OhanaPromega Corporation, Fitchburg, Wisconsin 53711 rachel.ohana@promega.com.
Promega (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) are prominent targets to new therapeutics for a range of diseases. Comprehensive assessments of their cellular interactions with bioactive compounds, particularly in a kinetic format, are imperative to the development of drugs with improved efficacy. Hence, we developed complementary cellular assays that enable equilibrium and real-time analyses of GPCR ligand engagement and consequent activation, measured as receptor internalization. These assays utilize GPCRs genetically fused to an N-terminal HiBiT peptide (1.3 kDa), which produces bright luminescence upon high-affinity complementation with LgBiT, an 18-kDa subunit derived from NanoLuc. The cell impermeability of LgBiT limits signal detection to the cell surface and enables measurements of ligand-induced internalization through changes in cell-surface receptor density. In addition, bioluminescent resonance energy transfer is used to quantify dynamic interactions between ligands and their cognate HiBiT-tagged GPCRs through competitive binding with fluorescent tracers. The sensitivity and dynamic range of these assays benefit from the specificity of bioluminescent resonance energy transfer and the high signal intensity of HiBiT/LgBiT without background luminescence from receptors present in intracellular compartments. These features allow analyses of challenging interactions having low selectivity or affinity and enable studies using endogenously tagged receptors. Using the β-adrenergic receptor family as a model, we demonstrate the versatility of these assays by utilizing the same HiBiT construct in analyses of multiple aspects of GPCR pharmacology. We anticipate that this combination of target engagement and proximal functional readout will prove useful to the study of other GPCR families and the development of new therapeutics.

Indexed as

LuminescenceAllosteric RegulationBinding, CompetitiveBioluminescence Resonance Energy Transfer TechniquesCell MembraneEnergy TransferHEK293 CellsHumansKineticsLigandsLuciferasesPeptide FragmentsProtein BindingProtein TransportReceptors, Adrenergic, beta-2LigandsLuciferasesPeptide FragmentsReceptors, Adrenergic, beta-2adrenergic receptorbioluminescencebioluminescence resonance energy transfer (BRET)endogenous taggingG protein-coupled receptor (GPCR)HiBiTkineticsligand engagementNanoLucreceptor internalization

Identifiers

PMID32107310
PMCPMC7152755
OpenAlexW3006851110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.